Basiliximab, previously referred to as CHI 621 and possessing the chemical identifier 179045-86-4, represents a antibody agent utilized primarily in preventing acute rejection following organ grafting . This engineered antibody specifically interacts with the interleukin-2 (IL-2) sensor , effectively inhibiting IL-2 signaling and subsequently dimin